Free Trial
OTCMKTS:QBIO

Q BioMed (QBIO) Stock Price, News & Analysis

Q BioMed logo
$0.0001 0.00 (0.00%)
As of 03:11 PM Eastern

About Q BioMed Stock (OTCMKTS:QBIO)

Key Stats

Today's Range
$0.0001
$0.0001
50-Day Range
N/A
52-Week Range
$0.00
$0.03
Volume
420,671 shs
Average Volume
55,114 shs
Market Capitalization
$14,509.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

Receive QBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Q BioMed and its competitors with MarketBeat's FREE daily newsletter.

QBIO Stock News Headlines

Q BioMed Inc
Orchestra Biomed Reports Q3 2024 Financial Results
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
A Powerful New Tool for Biomedical Research
See More Headlines

QBIO Stock Analysis - Frequently Asked Questions

Q BioMed's stock was trading at $0.0002 on January 1st, 2025. Since then, QBIO shares have decreased by 50.0% and is now trading at $0.0001.
View the best growth stocks for 2025 here
.

Q BioMed Inc. (OTCMKTS:QBIO) announced its quarterly earnings results on Wednesday, July, 14th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04. The company had revenue of $0.05 million for the quarter.

Shares of QBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Q BioMed investors own include Intel (INTC), Washington Trust Bancorp (WASH), Cisco Systems (CSCO), Nokia Oyj (NOK), NVIDIA (NVDA), Micron Technology (MU) and NewAge (NBEV).

Company Calendar

Last Earnings
7/14/2021
Today
5/08/2025
Fiscal Year End
11/30/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:QBIO
Previous Symbol
NASDAQ:QBIO
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$280,000.00
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
104,178,000
Market Cap
$14,509.50
Optionable
Not Optionable
Beta
2.22
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (OTCMKTS:QBIO) was last updated on 5/8/2025 by MarketBeat.com Staff
From Our Partners